Supplementary file 1: Search strategy

Search strategy – Embase

1. *rheumatoid arthritis/
2. "rheumatoid arthritis".ti,ab,kw.
3. 1 OR 2
4. infliximab.ti,ab,kw.
5. *infliximab/
6. remicade.ti,ab,kw.
7. remsima.ti,ab,kw.
8. inflectra.ti,ab,kw.
9. humira.ti,ab,kw.
10. *adalimumab/
11. adalimumab.ti,ab,kw.
12. cimzia.ti,ab,kw.
13. *certolizumab pegol/
14. (certolizumab adj2 pegol).ti,ab,kw.
15. enbrel.ti,ab,kw.
16. *etanercept/
17. etanercept.ti,ab,kw.
18. benepali.ti,ab,kw.
19. simponi.ti,ab,kw.
20. *golimumab/
21. golimumab.ti,ab,kw.
22. bDMARD$.ti,ab,kw.
23. biologic$ DMARD$.ti,ab,kw.
24. *tumor necrosis factor antibody/
25. anti-tnf.ti,ab,kw.
26. anti-tumor necrosis factor.ti,ab,kw.
27. anti-tumour necrosis factor.ti,ab,kw.
28. Tnfi.ti,ab,kw.
29. tnf inhibition.ti,ab,kw.
30. tnf inhibitor.ti,ab,kw.
31. Tnf inhibitors.ti,ab,kw.
32. or/4-31
33. biological marker/
34. biomarker$.ti,ab,kw.
35. predict$.ti,ab,kw.
36. predictive value/
37. "sensitivity and specificity"/
38. receiver operating characteristic/
39. Sensitivity.ti,ab,kw.
40. Specificity.ti,ab,kw.
41. Or/33-40
42. Respons$.ti,ab,kw.
43. Remission.ti,ab,kw.
44. "Disease activity".ti,ab,kw.
45. ACR-20.ti,ab,kw.
46. ACR-50.ti,ab,kw.
47. ACR-70.ti,ab,kw.
48. DAS.ti,ab,kw.
49. DAS28.ti,ab,kw.
50. DAS44.ti,ab,kw.
51. CDAI.ti,ab,kw.
52. SDAI.ti,ab,kw.
53. Or/42-52
54. 3 and 32 and 41 and 53

Search strategy – Pubmed

1. "rheumatoid arthritis"[Title/Abstract]
2. Arthritis, Rheumatoid[Mesh:NoExp]
3. 1 or 2
4. Adalimumab[Title/Abstract]
5. bDMARD*[Title/Abstract]
6. "biologic* DMARD*"[Title/Abstract]
7. Humira[Title/Abstract]
8. "Adalimumab"[Mesh:noexp]
9. Certolizumab[Title/Abstract]
10. Cimzia[Title/Abstract]
11. "Certolizumab Pegol"[Mesh:noexp]
12. Etanercept[Title/Abstract]
13. Enbrel[Title/Abstract]
14. Benepali[Title/Abstract]
15. "Etanercept"[Mesh:noexp]
16. Golimumab[Title/Abstract]
17. Simponi[Title/Abstract]
18. Infliximab[Title/Abstract]
19. Remicade[Title/Abstract]
20. Remsima[Title/Abstract]
21. Inflectra[Title/Abstract]
22. "Infliximab"[Mesh:noexp]
23. "Tumor Necrosis Factor-alpha/antagonists and inhibitors"[Mesh:noexp]
24. "anti-tnf"[Title/Abstract]
25. "anti-tumor necrosis factor"[Title/Abstract]
26. "anti-tumour necrosis factor"[Title/Abstract]
27. "tnfi"[Title/Abstract]
28. "tnf inhibition"[Title/Abstract]
29. "tnf inhibitor"[Title/Abstract]
30. "tnf inhibitors"[Title/Abstract]
31. Or/4-30
32. Biological Markers[Mesh:NoExp]
33. biomarker*[Title/Abstract]
34. predict*[Title/Abstract]
35. Predictive Value of Tests[Mesh:NoExp]
36. Sensitivity and Specificity[Mesh:NoExp]
37. ROC Curve[Mesh:NoExp]
38. Sensitivity[Title/Abstract]
39. Specificity[Title/Abstract]
40. Or/32-39
41. Respons*[tiab]
42. Remission[tiab]
43. "Disease activity"[tiab]
44. "ACR 20"[tiab]
45. "ACR 50"[tiab]
46. "ACR 70"[tiab]
47. DAS[tiab]
48. DAS28[tiab]
49. DAS44[tiab]
50. CDAI[tiab]
51. SDAI[tiab]
52. Or/41-51
53. 3 and 31 and 40 and 52

Search strategy – Cochrane library

1. MeSH descriptor: [Arthritis, Rheumatoid] this term only
2. (rheumatoid arthritis):ti,ab,kw
3. 1 or 2
4. Adalimumab:ti,ab,kw
5. bDMARD*:ti,ab,kw
6. "biologic* DMARD*":ti,ab,kw
7. Humira:ti,ab,kw
8. MeSH descriptor: [Adalimumab] this term only
9. Certolizumab:ti,ab,kw
10. Cimzia:ti,ab,kw
11. MeSH descriptor: [Certolizumab Pegol] this term only
12. Etanercept:ti,ab,kw
13. Enbrel:ti,ab,kw
14. Benepali:ti,ab,kw
15. MeSH descriptor: [Etanercept] this term only
16. Golimumab:ti,ab,kw
17. Simponi:ti,ab,kw
18. Infliximab:ti,ab,kw
19. Remicade:ti,ab,kw
20. Remsima:ti,ab,kw
21. Inflectra:ti,ab,kw
22. MeSH descriptor: [Infliximab] this term only
23. MeSH descriptor: [Tumor Necrosis Factor Inhibitors] this term only
24. "anti-tnf":ti,ab,kw
25. "anti-tumor necrosis factor":ti,ab,kw
26. "anti-tumour necrosis factor":ti,ab,kw
27. "tnfi":ti,ab,kw
28. "tnf inhibition":ti,ab,kw
29. "tnf inhibitor":ti,ab,kw
30. "tnf inhibitors":ti,ab,kw
31. Or/4-30
32. Biological Markers[Mesh:NoExp]
33. biomarker*:ti,ab,kw
34. predict*:ti,ab,kw
35. Predictive Value of Tests[Mesh:NoExp]
36. Sensitivity and Specificity[Mesh:NoExp]
37. ROC Curve[Mesh:NoExp]
38. sensitivity:ti,ab,kw
39. specificity:ti,ab,kw
40. or/32-39
41. Respons*:ti,ab,kw
42. Remission:ti,ab,kw
43. "Disease activity":ti,ab,kw
44. "ACR 20":ti,ab,kw
45. "ACR 50":ti,ab,kw
46. "ACR 70":ti,ab,kw
47. DAS:ti,ab,kw
48. DAS28:ti,ab,kw
49. DAS44:ti,ab,kw
50. CDAI:ti,ab,kw
51. SDAI:ti,ab,kw
52. Or/41-51
53. 3 and 31 and 40 and 52

Supplementary file 2: Exclusion reasons full text judgement

Author	Year	Reason of exclusion
Ajeganova, S., et al.	2011	No Sensitivity/specificity calculatable
Akdemir, G., et al.	2016	Definition of response
Alessandri, C., et al.	2004	N<50
Ammitzbøll, C. G., et al.	2013	No sensitivity/specificity calculatable
Andersen, T., et al.	2015	No sensitivity/specificity calculatable
Anecchino, C., et al.	2015	No sensitivity/specificity calculatable
Aterido, A., et al.	2019	No sensitivity/specificity calculatable
Atzeni, F., et al.	2009	No sensitivity/specificity calculatable
Atzeni, F., et al.	2014	Duration of follow-up
Ayubi, E. and S. Safiri	2018	No original data
Badot, V., et al.	2009	N<50
Baganz, L., et al.	2019	No sensitivity/specificity calculatable
Baker, J. F., et al.	2012	No sensitivity/specificity calculatable
Banse, C., et al.	2017	N<50
Barnabe, C., et al.	2014	Duration of follow-up
Barrera, P., et al.	2002	No sensitivity/specificity calculatable
Bazzichi, L., et al.	2012	No original data
Bendtzen, K., et al.	2006	Biomarker not at baseline
Bergman, M. J., et al.	2020	No original data
Bobbio-Pallavicini, F., et al.	2007	Duration of follow-up
Bosello, S., et al.	2011	N<50
Brahe, C. H., et al.	2019	No sensitivity/specificity calculatable
Brahe, C. H., et al.	2018	Duration of follow-up
Braun-Moscovici, Y., et al.	2006	N<50
Buch, M. H., et al.	2005	No sensitivity/specificity calculatable
Buch, M. H., et al.	2008	No laboratory biomarker
Burmester, G. R., et al.	2008	Definition of response
Cacciapaglia, F., et al.	2014	No sensitivity/specificity calculatable
Cacciapaglia, F., et al.	2014	N<50
Canet et al.	2019	No sensitivity/specificity calculatable
Canhão, H., et al.	2012	No sensitivity/specificity calculatable
Canhão, H., et al.	2015	No sensitivity/specificity calculatable
Castro-Villegas et al.	2015	Biomarker not at baseline
Ceccarelli, F., et al.	2012	No sensitivity/specificity calculatable
Chara, L., et al.	2012	N<50
Chatzikyriakidou, A., et al.	2007	Duration of follow-up
Chen, D. Y., et al.	2011	N<50
Cheng et al	2020	No sensitivity/specificity calculatable
Choi, B. Y., et al.	2014	N<50
Ciechomska, M., et al.	2018	N<50
Citro, A., et al.	2015	N<50
Conigliaro, P., et al.	2017	No sensitivity/specificity calculatable
Criswell, L. A., et al.	2004	Duration of follow-up
Cuchacovich, M., et al.	2004	N<50
Cuchacovich, M., et al.	2008	No sensitivity/specificity calculatable
Cui, J., et al.	2013	No sensitivity/specificity calculatable
Cui, J., et al.	2017	Biomarker not predefined
Cuppen, B. V. J., et al.	2018	Exclusion of moderate responders
Cuppen, B. V., et al.	2016	N<50
Cuppen, B. V., et al.	2016	Exclusion of moderate responders

Cuppen, B., et al.	2018	No sensitivity/specificity calculatable
Curtis, J. R., et al.	2012	N<50
Curtis, J. R., et al.	2013	Not solely TNFi
Curtis, J. R., et al.	2018	Not solely TNFi
Daien, C. I., et al.	2014	N<50
Dejaco, C., et al.	2009	N<50
Dejaco, C., et al.	2010	N<50
Dennis, G., Jr., et al.	2014	No sensitivity/specificity calculatable
Di Muzio, G., et al.	2011	No sensitivity/specificity calculatable
Dirven, L., et al.	2012	Definition of response
Ellegaard, K., et al.	2011	Definition of response
Ercan, A., et al.	2012	No sensitivity/specificity calculatable
Erlandsson, M. C., et al.	2012	No sensitivity/specificity calculatable
Ernestam, S., et al.	2007	N<50
Fabre, S., et al.	2008	N<50
Fernández-Nebro, A., et al.	2007	Definition of response
Ferreiro-Iglesias, A., et al.	2019	No sensitivity/specificity calculatable
Ferreiro-Iglesias, A., et al.	2016	No sensitivity/specificity calculatable
Folkersen, L., et al.	2016	No sensitivity/specificity calculatable
Fu, J., et al.	2018	Not solely TNFi
Gabay, C., et al.	2020	Definition of response
García-Arias, M., et al.	2013	N<50
González-Alvaro, I., et al.	2007	No sensitivity/specificity calculatable
Guan, Y., et al.	2019	No sensitivity/specificity calculatable
Guo, X., et al.	2019	Duration of follow-up
Halvorsen, E. H., et al.	2009	N<50
Hamann, P. D. H., et al.	2019	No sensitivity/specificity calculatable
Hambardzumyan, K., et al.	2019	No sensitivity/specificity calculatable
Hambardzumyan, K., et al.	2017	Duration of follow-up
Han, B. K., et al.	2016	N<50
Hattori, Y., et al.	2018	No sensitivity/specificity calculatable
Hayashi, S., et al.	2016	N<50
Hirata, S., et al.	2015	N<50
Honne, K., et al.	2016	Biomarker not predefined
Hoxha, A., et al.	2016	N<50
Huang, Q. L., et al.	2017	Biomarker not predefined
Hueber, W., et al.	2009	N<50
Isgren, A., et al.	2012	Cross sectional
Izumi, K., et al.	2015	No sensitivity/specificity calculatable
Jančić et al.	2013	No original data
Jonsdottir, T., et al.	2004	N<50
Julià A et al.	2015	No sensitivity/specificity calculatable
Julià A et al.	2021	No sensitivity/specificity calculatable
Karlsson, J. A., et al.	2008	No laboratory biomarker
Kastbom A. et al.	2007	No sensitivity/specificity calculatable
Kavanaugh, A., et al.	2013	No laboratory biomarker
Kim, T. H., et al.	2014	No original data
Klaasen R. et al.	2010	No original data
Kleinert, S., et al.	2012	No laboratory biomarker
Kobayashi, T., et al.	2016	N<50
Koga, T., et al.	2011	N<50
Koiwa, M., et al.	2016	No sensitivity/specificity calculatable
Krintel, S. B., et al.	2016	No sensitivity/specificity calculatable

Kubo, S., et al.	2018	No sensitivity/specificity calculatable
Levitsky, A., et al.	2015	Duration of follow-up
Ling, S. F., et al.	2020	Not solely TNFi
Liu, C., et al.	2008	Biomarker not predefined
Lopez-Rodriguez, R., et al.	2018	No sensitivity/specificity calculatable
Magill, L., et al.	2018	N<50
Mancarella, L., et al.	2007	Exclusion of patient group
Marotte, H., et al.	2008	Same data (Marotte 2006 included)
Márquez, A., et al.	2014	No sensitivity/specificity calculatable
Martin, W. J., et al.	2014	No laboratory biomarker
Marwa, O. S., et al.	2017	Not solely TNFi
Massey, J., et al.	2018	Biomarker not predefined
Mirkov, M. U., et al.	2013	No sensitivity/specificity calculatable
Misko, T. P., et al.	2013	N<50
Miwa, Y., et al.	2017	Other bDMARD
Miwa, Y., et al.	2017	No sensitivity/specificity calculatable
Miyoshi, F., et al.	2016	N<50
Mohammed, R. H., et al.	2015	No sensitivity/specificity calculatable
Möller, B., et al.	2018	Definition of response
Montes, A., et al.	2014	No sensitivity/specificity calculatable
Mourão, A. F., et al.	2017	No sensitivity/specificity calculatable
Mugnier, B. and J. Roudier	2004	Editorial
Nair, S. C., et al.	2016	No sensitivity/specificity calculatable
Nair, S. C., et al.	2016	Editorial
Nakagawa, J., et al.	2017	No sensitivity/specificity calculatable
Nakamura, S., et al.	2016	Biomarker not predefined
Nguyen, D. X., et al.	2018	N<50
Nguyen, M. V. C., et al.	2018	No sensitivity/specificity calculatable
Niki, Y. and T. Takeuchi	2012	Not in English
Nordal, H. H., et al.	2017	No sensitivity/specificity calculatable
Nozaki, Y., et al.	2010	N<50
Obry, A., et al.	2014	N<50
Ongaro, A., et al.	2008	Exclusion of patient group
Ortea, I., et al.	2012	N<50
Ortea, I., et al.	2016	N<50
Oswald, M., et al.	2015	Biomarker not predefined
Page, T. H., et al.	2012	No sensitivity/specificity calculatable
Paran, D., et al.	2018	N<50
Pérez-Sánchez, C., et al.	2017	No sensitivity/specificity calculatable
Plant, D., et al.	2011	No sensitivity/specificity calculatable
Plant, D., et al.	2012	No sensitivity/specificity calculatable
Plant, D., et al.	2016	No sensitivity/specificity calculatable
Pomirleanu, C., et al.	2013	No sensitivity/specificity calculatable
Potter, C., et al.	2009	No sensitivity/specificity calculatable
Ranganathan, P.	2015	No original data
Rinaudo-Gaujous, M., et al.	2019	No sensitivity/specificity calculatable
Sande, J. S., et al.	2019	No sensitivity/specificity calculatable
Santos-Moreno, P., et al.	2019	Duration of follow-up
Schotte, H., et al.	2005	Duration of follow-up
Schotte, H., et al.	2015	Duration of follow-up
Seitz, M., et al.	2007	No sensitivity/specificity calculatable
Sieberts, S. K., et al.	2016	No sensitivity/specificity calculatable
Smith, S. L., et al.	2015	No sensitivity/specificity calculatable

Smith, S. L., et al.	2016	Exclusion of moderate responders
Smith, S. L., et al.	2017	No sensitivity/specificity calculatable
Smolen, J. S., et al.	2018	MTX
Smolen, J. S., et al.	2018	No sensitivity/specificity calculatable
Sode J. et al.	2015	Duration of follow-up
Sode, J., et al.	2018	No sensitivity/specificity calculatable
Sode, J., et al.	2018	No sensitivity/specificity calculatable
Soriano, E. R., et al.	2018	No sensitivity/specificity calculatable
Soto, L., et al.	2011	Exclusion of patient group
Spiliopoulou, A., et al.	2019	No sensitivity/specificity calculatable
Suarez-Gestal, M., et al.	2010	No sensitivity/specificity calculatable
Takeuchi, T., et al.	2011	No sensitivity/specificity calculatable
Takeuchi, T., et al.	2017	No sensitivity/specificity calculatable
Tatar, Z., et al.	2016	Exclusion of moderate responders
Thomson, T. M., et al.	2015	Duration of follow-up
Torices, S., et al.	2016	No sensitivity/specificity calculatable
Trocmé, C., et al.	2009	Exclusion of patient group
Tsukahara, S., et al.	2008	N<50
Tsuzaka, K., et al.	2010	Duration of follow-up
Tweehuysen, L., et al.	2018	Definition of response
Tweehuysen, L., et al.	2019	No laboratory biomarker
Tweehuysen, L., et al.	2018	No sensitivity/specificity calculatable
Umićević Mirkov, M., et al.	2013	Biomarker not predefined
Uno, K., et al.	2015	N<50
Váradi, C., et al.	2015	No sensitivity/specificity calculatable
Vasilopoulos, Y., et al.	2011	Exclusion of moderate responders
Vastesaeger, N., et al.	2016	No sensitivity/specificity calculatable
Visvanathan, S., et al.	2007	No sensitivity/specificity calculatable
Visvanathan, S., et al.	2009	No sensitivity/specificity calculatable
Visvanathan, S., et al.	2010	Biomarker not at baseline
Wampler Muskardin, T., et al.	2020	No sensitivity/specificity calculatable
Wielińska, J., et al.	2020	No sensitivity/specificity calculatable
Wolbink, G. J., et al.	2005	Biomarker not at baseline
Yazici, S., et al.	2010	N<50
Yuasa, S., et al.	2013	No sensitivity/specificity calculatable
Yukawa, N., et al.	2011	Duration of follow-up
Yunchun, L., et al.	2018	No sensitivity/specificity calculatable
Zervou, M. I., et al.	2013	No sensitivity/specificity calculatable

Supplementary file 3: Risk of bias assessment for included studies using the QUIPS tool[1] (n=41).

	Study Participation	Study Attrition	Prognostic factor Measurement	Outcome Measurement
Abhishek et al. (1)	Low	High	Moderate	Low
Acosta-Colman et al. (2)	Moderate	Low	Low	Low
Avila-Pedretti et al. (3)	Moderate	Low	Low	Low
Blaschke et al. (4)	Moderate	Low	Low	Low
Bystrom et al. (5)	Moderate	High	Moderate	Low
Cañete et al. (6)	Moderate	Moderate	Low	Low
Cañete et al. (7)	High	Low	Low	Low
Choi et al. (8)	Moderate	Low	Moderate	Low
Conigliaro et al. (9)	Low	Low	Low	Low
Coulthard et al. (10)	Low	High	Low	Low
Cuchacovich et al. (11)	Moderate	Low	Low	Low
Dávila-Fajardo et al. (12)	Moderate	Low	Low	Low
Dávila-Fajardo et al. (13)	Moderate	Low	Low	Low
Ding et al. (14)	Moderate	Moderate	Moderate	Low
Fisher et al. (15)	Low	Low	Low	Low
Guis et al. (16)	Moderate	Low	Low	Low
Hyrich et al. (17)	Low	Moderate	Low	Low
Iwaszko et al. (18)	Moderate	Moderate	Low	Low
Iwaszko et al. (19)	Moderate	Low	Low	Low
Jamnitski et al. (20)	Low	Moderate	Low	Low
Jancic et al. (21)	Low	Low	Low	Low
Kang et al. (22)	Moderate	Low	Low	Low
Klaasen et al. (23)	Low	Low	Low	Low
Lee et al. (24)	Moderate	Moderate	Moderate	Low
Lequerré et al. (25)	Low	Low	Low	Low
Marotte et al. (26)	Low	Low	Low	Low
Matsudaira et al. (27)	Moderate	Low	Low	Low
McGeough et al. (28)	High	Low	Low	Low
Miceli-Richard et al. (29)	Moderate	Low	Low	Low
Montes et al. (30)	Moderate	Low	Moderate	Low
Morales-Lara et al. (31)	High	Low	Low	Low
Mugnier et al. (32)	Low	Low	Low	Low
Nishimoto et al. (33)	Moderate	Low	Low	Low
Padyukov et al. (34)	Moderate	Low	Low	Low
Pers et al. (35)	High	Low	Low	Low
Radstake et al. (36)	Moderate	Low	Low	Low
Salgado et al. (37)	High	Low	Low	Low
Shi et al. (38)	Low	Low	Low	Low
Skapenko et al. (39)	Moderate	Low	Low	Low
Wampler Muskardin et al. (40)	Moderate	Low	Low	Low
Zhao et al. (41)	Moderate	Low	Low	Low

[1]Items 5. Study Confounding and 6. Statistical Analysis and Reporting were not scored because we extracted unadjusted and unanalyzed data from the studies.

Supplementary file 4: Biomarkers studied once or twice

Author	Biomarker	Response criteria	Total n	Sensitivity	Specificity	PPV	NPV	LL+	LL-
Acosta-Colman	PDE3A–SLCO1C1 (rs3794271)	EULAR	313	0.93	0.18	0.78	0.45	1.13	0.4
Bystrom*	GM-CSF	EULAR**	97	0.82	0.71	0.88	-	2.88	0.2
Canete1	DS-TNFR2	EULAR	64	0.27	0.74	0.71	0.30	1.01	1.0
Choi*	MRP8/14 (calprotectin)	EULAR	ADA: 86 IFX: 60	0.57 0.62	0.71 0.86	0.86 0.93	0.35 0.43	1.97 4.43	0.6 0.4
Conigliaro	PSORS1C1 (rs2233945) C>A	EULAR	163	0.34	0.55	0.67	0.23	0.74	1.2
Conigliaro	PTPN2 (rs7234029) A>G	EULAR	160	0.27	0.60	0.65	0.23	0.67	1.2
Conigliaro	STAT4 (rs7574865) G>T	EULAR	163	0.44	0.45	0.68	0.23	0.80	1.2
Conigliaro	TRAF3IP2 (rs33980500) C>T	EULAR	162	0.13	0.84	0.68	0.26	0.80	1.0
Coulthard	MAP2K6 (rs11656130) T/G	EULAR	918	0.68	0.22	0.78	0.14	0.87	1.5
Coulthard	MAP2K6 (rs2716191) T/C	EULAR	905	0.71	0.34	0.81	0.23	1.08	0.9
Coulthard	MAPK14 (rs916344) C/G	EULAR	918	0.52	0.49	0.81	0.20	1.02	1.0
Coulthard	MAPKAPK2 (rs4240847) C/A	EULAR	901	0.43	0.47	0.77	0.17	0.81	1.2
Coulthard	RPS6KA4 (rs475032) G/C	EULAR	903	0.61	0.39	0.80	0.20	1.00	1.0
Coulthard	RPS6KA5 (rs1286076) C/T	EULAR	900	0.47	0.53	0.80	0.20	1.01	1.0
Coulthard	RPS6KA5 (rs1286112) C/G	EULAR	920	0.47	0.50	0.79	0.19	0.94	1.1
Davila-Fajardo2	IL-6 (rs1800795) C/G	EULAR	191	0.91	0.10	0.85	0.17	1.01	0.9
Ding*	ESR	ACR20	90	0.88	0.61	-	-	2.24	0.2
Ding*	IL-34	ACR20	90	0.77	0.71	-	-	2.67	0.3
Fisher	Anti-CEP-1	EULAR	450	0.38	0.59	0.78	0.21	0.94	1.0
Fisher	Anti-cFib	EULAR	436	0.74	0.22	0.78	0.19	0.95	1.2
Fisher	Anti-cVim	EULAR	436	0.42	0.59	0.79	0.21	1.03	1.0
Iwaszko	NKG2D (rs1049174) C/G	EULAR	270	0.56	0.43	0.95	0.05	0.98	1.0
Iwaszko	NKG2D (rs1154831) C/A	EULAR	270	0.33	0.64	0.94	0.05	0.92	1.0
Iwaszko	NKG2D (rs2255336) G/A	EULAR	270	0.38	0.71	0.96	0.06	1.33	0.9
Iwaszko	HLA-E rs1264457	EULAR	209	0.67	0.27	0.94	0.04	0.92	1.2
Iwaszko	HLA-E rs1059150	EULAR	198	0.55	0.18	0.92	0.02	0.67	2.5
Jamnitski	Anti-IFX or anti-ADA	EULAR	89	0.61	0.78	0.91	0.33	2.73	0.5
Jančić	IL-6 −174G/C	ΔDAS>1.2	73	0.11	0.82	0.78	0.14	0.62	1.1
Jančić	combined IL-6 + TNFa (GC/GG reference)	ΔDAS>1.2	73	0.61	0.36	0.84	0.14	0.96	1.1
Lee	NLR	EULAR	73	0.46	0.67	0.94	0.10	1.39	0.8

Author	Marker	Outcome	N						
Lee	PLR	EULAR	73	0.46	0.50	0.91	0.08	0.93	1.1
Lequerré	ACAST-C27	EULAR	76	0.09	0.86	0.50	0.37	0.62	1.1
Lequerré	ACAST-DI	EULAR	76	0.17	0.93	0.80	0.41	2.47	0.9
Lequerré	AKA	EULAR	76	0.36	0.59	0.59	0.36	0.87	1.1
Lequerré	Anti-a-enolase	EULAR	76	0.30	0.79	0.70	0.41	1.44	0.9
Lequerré	anti-G6PI	EULAR	76	0.11	0.86	0.56	0.37	0.77	1.0
Lequerré	APF	EULAR	76	0.53	0.34	0.57	0.31	0.81	1.4
Lequerré	DPYD	EULAR	76	1.00	0.03	0.63	1.00	1.04	0.0
Lequerré	OPG	EULAR	76	1.00	0.07	0.64	1.00	1.07	0.0
Lequerré	PYD	EULAR	76	0.74	0.21	0.60	0.33	0.94	1.2
Lequerré	sRANKL	EULAR	76	0.17	0.76	0.53	0.36	0.71	1.1
Marotte	IL-1B (+3954)	ACR20	198	0.37	0.49	0.59	0.29	0.74	1.3
Marotte	IL-1RN (+2018)	ACR20	262	0.44	0.56	0.50	0.50	1.00	1.0
Matsudaira	ANA	EULAR	188	0.94	0.13	0.80	0.36	1.08	0.5
Matsudaira	Anti-dsDNA	EULAR	187	0.02	0.90	0.43	0.19	0.20	1.1
Matsudaira	Anti-La/SSA antibodies	EULAR	188	0.02	1.00	1.00	0.21	∞	1.0
Matsudaira	Anti-Ro/SSA antibodies	EULAR	188	0.12	0.67	0.58	0.17	0.36	1.3
McGeough	KIR2DS2	ΔDAS>1.2 or DAS<3.2	64	0.68	0.67	0.70	0.65	1.68	0.7
McGeough	HLA-C heterozygous /homozygous	ΔDAS>1.2 or DAS<3.2	64	0.56	0.67	0.66	0.57	2.03	0.5
Montes	FCGR2B rs1050501 T/C	EULAR	377	0.27	0.79	0.84	0.22	1.32	0.9
Montes	FCGR3A rs396991 T/G	EULAR	408	0.64	0.23	0.70	0.19	0.84	1.5
Montes	FCRGT 3/3 / 2/3	EULAR	251	0.18	0.71	0.71	0.18	0.61	1.2
Morales-Lara	TRAILR1 rs20575	EULAR	89	0.66	0.88	0.90	0.60	5.45	0.4
Morales-Lara	TNFR1A rs767455	EULAR	89	0.32	0.73	0.67	0.39	1.18	0.9
Nishimoto	TRAF1 (+16860) A/G	EULAR	101	0.46	0.20	0.84	0.04	0.58	2.7
Padyukov	IL-10 G/A	ACR20 or EULAR	123	0.73	0.33	0.82	0.23	1.09	0.8
Padyukov	IL1RN A1/A2	ACR20 or EULAR	123	0.30	0.46	0.70	0.14	0.56	1.5
Padyukov	TGFB1 G/C	ACR20 or EULAR	123	0.15	0.83	0.79	0.19	0.91	1.0
Radstake	MIF-173 G/C	EULAR	90	0.41	0.77	0.81	0.34	1.76	0.8
Radstake	MIF-CATT7	EULAR	90	0.27	0.85	0.81	0.32	1.73	0.9
Shi*	IL-6 + survivin combined	ΔDAS>1.2	69	0.80	0.91	-	-	9.24	0.2
Skapenko	FcγRIIb (rs1050501) T/C	DAS<3.2	443	0.21	0.83	0.52	0.56	1.29	0.9
Skapenko	IL4R (rs1805010) A/G	DAS<3.2	443	0.66	0.32	0.45	0.53	0.97	1.1
Wampler Muskardin	IFN-B/a ratio	EULAR	79	0.74	0.54	0.65	0.65	1.61	0.5
Marotte	TNFA (-238)	ACR20	262	0.03	0.97	0.50	0.50	1.00	1.0
Miceli-Richard	TNFA (-238)	ACR50	360	0.08	0.96	0.57	0.60	1.93	1.0
Miceli-Richard	TNFA (-857) C/T	ACR50	357	0.21	0.86	0.51	0.61	1.49	0.9
Kang	TNFA (-857) C/T	ACR20	70	0.43	0.90	0.96	0.21	4.33	0.6
Davila-Fajardo3	FcGR3A (rs396991) F/V	EULAR**	301	0.62	0.38	0.53	0.47	1.00	1.0

Canete4	FcGR3A (rs396991) F/V	EULAR	77	0.57	0.33	0.57	0.33	0.86	1.3

*No absolute values given

**EULAR good response versus moderate + non responders

[1] Canete et al. 2011

[2] Davila-Fajardo et al. 2014

[3] Davila-Fajardo et al. 2015

[4] Canete et al. 2009

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

RMD Open

References

1.   Abhishek A, Butt S, Gadsby K, Zhang W, Deighton CM. Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers. J Clin Rheumatol. 2010;16(1):15-8.

2.   Acosta-Colman I, Palau N, Tornero J, Fernández-Nebro A, Blanco F, González-Alvaro I, et al. GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics. 2013;14(7):727-34.

3.   Avila-Pedretti G, Tornero J, Fernández-Nebro A, Blanco F, González-Alvaro I, Cañete JD, et al. Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis. PLoS One. 2015;10(4):e0122088.

4.   Blaschke S, Rinke K, Maring M, Flad T, Patschan S, Jahn O, et al. Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis. Arthritis Res Ther. 2015;17(1):45.

5.   Bystrom J, Clanchy FI, Taher TE, Al-Bogami MM, Muhammad HA, Alzabin S, et al. Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF(+) T Lymphocytes. Clin Rev Allergy Immunol. 2017;53(2):265-76.

6.   Cañete JD, Suárez B, Hernández MV, Sanmartí R, Rego I, Celis R, et al. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68(10):1547-52.

7.   Cañete JD, Albaladejo C, Hernández MV, Laínez B, Pinto JA, Ramírez J, et al. Clinical significance of high levels of soluble tumour necrosis factor-α receptor-2 produced by alternative splicing in rheumatoid arthritis: a longitudinal prospective cohort study. Rheumatology (Oxford). 2011;50(4):721-8.

8.   Choi IY, Gerlag DM, Herenius MJ, Thurlings RM, Wijbrandts CA, Foell D, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(3):499-505.

9.   Conigliaro P, Ciccacci C, Politi C, Triggianese P, Rufini S, Kroegler B, et al. Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 Genes Are Associated with the Response to TNF Inhibitors in Patients with Rheumatoid Arthritis. PLoS One. 2017;12(1):e0169956.

10.   Coulthard LR, Taylor JC, Eyre S, Robinson JI, Wilson AG, Isaacs JD, et al. Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis. 2011;70(1):98-103.

11.   Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, Pacheco D, et al. Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol. 2006;35(6):435-40.

12.   Dávila-Fajardo CL, Márquez A, Pascual-Salcedo D, Moreno Ramos MJ, García-Portales R, Magro C, et al. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. Pharmacogenet Genomics. 2014;24(1):1-5.

13.   Dávila-Fajardo CL, van der Straaten T, Baak-Pablo R, Medarde Caballero C, Cabeza Barrera J, Huizinga TW, et al. FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. Pharmacogenomics. 2015;16(4):373-81.

14.   Ding R, Li P, Song D, Zhang X, Bi L. Predictors of response to TNF-α antagonist therapy in Chinese rheumatoid arthritis. Clin Rheumatol. 2015;34(7):1203-10.

15.   Fisher BA, Plant D, Lundberg K, Charles P, Barton A, Venables PJ. Heterogeneity of anticitrullinated peptide antibodies and response to anti-tumor necrosis factor agents in rheumatoid arthritis. J Rheumatol. 2012;39(5):929-32.

16.   Guis S, Balandraud N, Bouvenot J, Auger I, Toussirot E, Wendling D, et al. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum. 2007;57(8):1426-30.

17.   Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006;45(12):1558-65.

18.   Iwaszko M, Świerkot J, Kolossa K, Jeka S, Wiland P, Bogunia-Kubik K. Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy. Clin Exp Immunol. 2015;182(3):270-7.

19.   Iwaszko M, Świerkot J, Kolossa K, Jeka S, Wiland P, Bogunia-Kubik K. Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis. Genes (Basel). 2018;9(2).

20.   Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011;70(2):284-8.

21.   Jančić I, Šefik-Bukilica M, Živojinović S, Damjanov N, Spasovski V, Kotur N, et al. Influence of Promoter Polymorphisms of the TNF-α (-308G/A) and IL-6 (-174G/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis. J Med Biochem. 2015;34(4):414-21.

22.   Kang CP, Lee KW, Yoo DH, Kang C, Bae SC. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford). 2005;44(4):547-52.

23.   Klaasen R, Cantaert T, Wijbrandts CA, Teitsma C, Gerlag DM, Out TA, et al. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study. Rheumatology (Oxford). 2011;50(8):1487-93.

24.   Lee HN, Kim YK, Kim GT, Ahn E, So MW, Sohn DH, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as predictors of 12-week treatment response and drug persistence of anti-tumor necrosis factor-α agents in patients with rheumatoid arthritis: a retrospective chart review analysis. Rheumatol Int. 2019;39(5):859-68.

25.   Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, et al. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology (Oxford). 2007;46(3):446-53.

26.   Marotte H, Pallot-Prades B, Grange L, Tebib J, Gaudin P, Alexandre C, et al. The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis. 2006;65(3):342-7.

27.   Matsudaira R, Tamura N, Sekiya F, Ogasawara M, Yamanaka K, Takasaki Y. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol. 2011;38(11):2346-54.

28.   McGeough CM, Berrar D, Wright G, Mathews C, Gilmore P, Cunningham RT, et al. Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy. Rheumatol Int. 2012;32(6):1647-53.

29.   Miceli-Richard C, Comets E, Verstuyft C, Tamouza R, Loiseau P, Ravaud P, et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis. 2008;67(4):478-84.

30.   Montes A, Perez-Pampin E, Joven B, Carreira P, Fernández-Nebro A, Del Carmen Ordóñez M, et al. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. Pharmacogenomics. 2015;16(4):333-45.

31.   Morales-Lara MJ, Cañete JD, Torres-Moreno D, Hernández MV, Pedrero F, Celis R, et al. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine. 2012;79(6):591-6.

32.   Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum. 2003;48(7):1849-52.

33.   Nishimoto T, Seta N, Anan R, Yamamoto T, Kaneko Y, Takeuchi T, et al. A single nucleotide polymorphism of TRAF1 predicts the clinical response to anti-TNF treatment in Japanese patients with rheumatoid arthritis. Clin Exp Rheumatol. 2014;32(2):211-7.

34.   Padyukov L, Lampa J, Heimbürger M, Ernestam S, Cederholm T, Lundkvist I, et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis. 2003;62(6):526-9.

35.   Pers YM, Cadart D, Rittore C, Ravel P, Daïen V, Fabre S, et al. TNFRII polymorphism is associated with response to TNF blockers in rheumatoid arthritis patients seronegative for ACPA. Joint Bone Spine. 2014;81(4):370-2.

36.   Radstake TR, Fransen J, Toonen EJ, Coenen MJ, Eijsbouts AE, Donn R, et al. Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritis. Ann Rheum Dis. 2007;66(11):1525-30.

37.   Salgado E, Campos J, Moreira-Navarrete V, Mulero J, Navarro F, Pérez-Pampín E, et al. Rheumatoid factor does not predict response to TNF antagonists in rheumatoid arthritis: three centers experience. Joint Bone Spine. 2013;80(4):438-40.

38.   Shi R, Chen M, Litifu B. Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis. Mod Rheumatol. 2018;28(1):126-32.

39.   Skapenko A, Smolen JS, Kavanaugh A, Arora V, Kupper H, Schulze-Koops H. Genetic markers associated with clinical and radiographic response in adalimumab plus methotrexate- or methotrexate-treated rheumatoid arthritis patients in OPTIMA. Clin Exp Rheumatol. 2019;37(5):783-90.

40.   Wampler Muskardin T, Vashisht P, Dorschner JM, Jensen MA, Chrabot BS, Kern M, et al. Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1757-62.

41.   Zhao J, Ye X, Zhang Z. The predictive value of serum soluble ICAM-1 and CXCL13 in the therapeutic response to TNF inhibitor in rheumatoid arthritis patients who are refractory to csDMARDs. Clin Rheumatol. 2020;39(9):2573-81.